Simulations Plus (SLP) Receives Average Recommendation of “Strong Buy” from Brokerages

Shares of Simulations Plus (NASDAQ:SLP) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price objective of $18.75 for the company and are anticipating that the company will post $0.13 EPS for the current quarter, according to Zacks. Zacks has also given Simulations Plus an industry rank of 81 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

SLP has been the topic of a number of recent research reports. ValuEngine raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research raised Simulations Plus from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Finally, BidaskClub cut Simulations Plus from a “hold” rating to a “sell” rating in a report on Friday, January 26th.

SLP stock traded down $0.15 during midday trading on Friday, hitting $16.85. The company’s stock had a trading volume of 41,316 shares, compared to its average volume of 57,547. Simulations Plus has a 1 year low of $11.00 and a 1 year high of $17.45. The stock has a market cap of $294.54, a P/E ratio of 49.56 and a beta of -0.56.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.11. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. The business had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.37 million. equities research analysts forecast that Simulations Plus will post 0.4 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Investors of record on Wednesday, April 25th will be issued a dividend of $0.06 per share. The ex-dividend date is Tuesday, April 24th. This represents a $0.24 dividend on an annualized basis and a yield of 1.42%. Simulations Plus’s dividend payout ratio (DPR) is 70.59%.

In related news, Chairman Walter S. Woltosz sold 18,500 shares of the stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $14.54, for a total transaction of $268,990.00. Following the sale, the chairman now owns 5,466,408 shares of the company’s stock, valued at approximately $79,481,572.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 33.45% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Montreal Can bought a new position in shares of Simulations Plus during the 4th quarter valued at about $104,000. The Manufacturers Life Insurance Company increased its position in shares of Simulations Plus by 13.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,923 shares of the technology company’s stock valued at $110,000 after purchasing an additional 1,085 shares during the last quarter. Strs Ohio increased its position in shares of Simulations Plus by 196.9% during the 4th quarter. Strs Ohio now owns 9,500 shares of the technology company’s stock valued at $152,000 after purchasing an additional 6,300 shares during the last quarter. Algert Global LLC bought a new position in shares of Simulations Plus during the 4th quarter valued at about $175,000. Finally, Wells Fargo & Company MN increased its position in shares of Simulations Plus by 234.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,028 shares of the technology company’s stock valued at $275,000 after purchasing an additional 11,931 shares during the last quarter. Institutional investors and hedge funds own 33.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Simulations Plus (SLP) Receives Average Recommendation of “Strong Buy” from Brokerages” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/04/15/simulations-plus-slp-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Get a free copy of the Zacks research report on Simulations Plus (SLP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Simulations Plus (SLP) Receives Average Recommendation of “Strong Buy” from Brokerages

Shares of Simulations Plus (NASDAQ:SLP) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price objective of $18.75 for the company and are anticipating that the company will post $0.13 EPS for the current quarter, according to Zacks. Zacks has also given Simulations Plus an industry rank of 81 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

SLP has been the topic of a number of recent research reports. ValuEngine raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research raised Simulations Plus from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Finally, BidaskClub cut Simulations Plus from a “hold” rating to a “sell” rating in a report on Friday, January 26th.

SLP stock traded down $0.15 during midday trading on Friday, hitting $16.85. The company’s stock had a trading volume of 41,316 shares, compared to its average volume of 57,547. Simulations Plus has a 1 year low of $11.00 and a 1 year high of $17.45. The stock has a market cap of $294.54, a P/E ratio of 49.56 and a beta of -0.56.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.11. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. The business had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.37 million. equities research analysts forecast that Simulations Plus will post 0.4 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Investors of record on Wednesday, April 25th will be issued a dividend of $0.06 per share. The ex-dividend date is Tuesday, April 24th. This represents a $0.24 dividend on an annualized basis and a yield of 1.42%. Simulations Plus’s dividend payout ratio (DPR) is 70.59%.

In related news, Chairman Walter S. Woltosz sold 18,500 shares of the stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $14.54, for a total transaction of $268,990.00. Following the sale, the chairman now owns 5,466,408 shares of the company’s stock, valued at approximately $79,481,572.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 33.45% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of Montreal Can bought a new position in shares of Simulations Plus during the 4th quarter valued at about $104,000. The Manufacturers Life Insurance Company increased its position in shares of Simulations Plus by 13.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,923 shares of the technology company’s stock valued at $110,000 after purchasing an additional 1,085 shares during the last quarter. Strs Ohio increased its position in shares of Simulations Plus by 196.9% during the 4th quarter. Strs Ohio now owns 9,500 shares of the technology company’s stock valued at $152,000 after purchasing an additional 6,300 shares during the last quarter. Algert Global LLC bought a new position in shares of Simulations Plus during the 4th quarter valued at about $175,000. Finally, Wells Fargo & Company MN increased its position in shares of Simulations Plus by 234.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,028 shares of the technology company’s stock valued at $275,000 after purchasing an additional 11,931 shares during the last quarter. Institutional investors and hedge funds own 33.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Simulations Plus (SLP) Receives Average Recommendation of “Strong Buy” from Brokerages” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/04/15/simulations-plus-slp-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Get a free copy of the Zacks research report on Simulations Plus (SLP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply